TY  - JOUR
A1  - Preißer, Felix
A1  - Chun, Felix
A1  - Banek, Séverine
A1  - Wenzel, Mike
A1  - Graefen, Markus
A1  - Steuber, Thomas
A1  - Tilki, Derya
A1  - Mandel, Philipp
T1  - Management and treatment options for patients with de novo and recurrent hormone-sensitive oligometastatic prostate cancer
T2  - Prostate international
N2  - Probably, patients with de novo (synchronous) and recurrent (metachronous) oligometastatic hormone-sensitive prostate cancer have different oncologic outcomes. Thus, we are challenged with different scenarios in clinical practice, where different treatment options may apply. In the last years, several prospective studies have focused on the treatment of patients with de novo oligometastatic hormone-sensitive prostate cancer. Not only the addition of systemic therapeutic treatments, such as chemotherapy with docetaxel, abiraterone, enzalutamide, and apalutamide, next to androgen deprivation therapy, demonstrated to improve outcomes in these patients but also local therapy of the primary has been demonstrated to improve outcomes of low-volume metastatic disease. Next to radiotherapy, also radical prostatectomy has been reported as a feasible and safe treatment option. Additional metastasis-directed therapy in de novo metastatic disease is currently examined by four trials. In the recurrent metastatic setting, less data are available, and it remains uncertain if patients can be treated in the same way as synchronous oligometastatic disease. Metastasis-directed therapy has demonstrated to prolong outcomes, while data on survival are still missing.
KW  - Local therapy
KW  - Metastasis-directed therapy
KW  - Oligometastatic
KW  - Prostate cancer
KW  - Systemic therapy
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/77967
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-779671
SN  - 2287-8882
VL  - 9
IS  - 3
SP  - 113
EP  - 118
PB  - Elsevier
CY  - Amsterdam
ER  -